Should I buy or sell Laboratory Co. of America stock right now?

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Laboratory Co. of America in the last year. There are currently 3 hold ratings and 11 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" LH shares. View LH analyst ratings or view top-rated stocks .

What is Laboratory Co. of America's stock price target for 2024?

14 analysts have issued 12-month target prices for Laboratory Co. of America's stock. Their LH share price targets range from $210.00 to $270.00. On average, they anticipate the company's share price to reach $243.50 in the next twelve months. This suggests a possible upside of 19.2% from the stock's current price. View analysts price targets for LH or view top-rated stocks among Wall Street analysts .

How have LH shares performed in 2024?

Laboratory Co. of America's stock was trading at $227.29 on January 1st, 2024. Since then, LH stock has decreased by 10.1% and is now trading at $204.26. View the best growth stocks for 2024 here .

When is Laboratory Co. of America's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, April 25th 2024. View our LH earnings forecast .

How can I listen to Laboratory Co. of America's earnings call?

Laboratory Co. of America will be holding an earnings conference call on Thursday, April 25th at 9:00 AM Eastern. Interested parties can register for or listen to the call using this link .

How were Laboratory Co. of America's earnings last quarter?

Laboratory Co. of America Holdings (NYSE:LH) posted its quarterly earnings data on Thursday, February, 15th. The medical research company reported $3.30 earnings per share for the quarter, beating the consensus estimate of $3.29 by $0.01. The medical research company had revenue of $3.03 billion for the quarter, compared to the consensus estimate of $3.02 billion. Laboratory Co. of America had a trailing twelve-month return on equity of 13.99% and a net margin of 3.24%. The firm's quarterly revenue was down 17.5% on a year-over-year basis. During the same period last year, the company earned $4.14 earnings per share. Read the conference call transcript .

How often does Laboratory Co. of America pay dividends? What is the dividend yield for Laboratory Co. of America?

Laboratory Co. of America declared a quarterly dividend on Thursday, April 11th. Investors of record on Tuesday, May 28th will be paid a dividend of $0.72 per share on Wednesday, June 12th. This represents a $2.88 dividend on an annualized basis and a yield of 1.41%. The ex-dividend date is Friday, May 24th. Read our dividend analysis for LH .

Is Laboratory Co. of America a good dividend stock?

Laboratory Co. of America (NYSE:LH) pays an annual dividend of $2.88 per share and currently has a dividend yield of 1.40%. The dividend payout ratio is 61.67%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, LH will have a dividend payout ratio of 17.99% next year. This indicates that the company will be able to sustain or increase its dividend. Read our dividend analysis for LH .

What ETFs hold Laboratory Co. of America's stock?

ETFs with the largest weight of Laboratory Co. of America (NYSE:LH) stock in their portfolio include Amplify Treatments, Testing and Advancements ETF (GERM) , Cambiar Aggressive Value ETF (CAMX) , Vesper U.S. Large Cap Short-Term Reversal Strategy ETF (UTRN) , Global X Telemedicine & Digital Health ETF (EDOC) , iShares U.S. Healthcare Providers ETF (IHF) , LeaderShares AlphaFactor Tactical Focused ETF (LSAT) , BlackRock Large Cap Value ETF (BLCV) and Thrivent Small-Mid Cap ESG ETF (TSME) .

What guidance has Laboratory Co. of America issued on next quarter's earnings?

Laboratory Co. of America updated its FY 2024 earnings guidance on Friday, February, 16th. The company provided earnings per share (EPS) guidance of 14.300-15.400 for the period, compared to the consensus earnings per share estimate of 14.600. The company issued revenue guidance of $12.7 billion-$13.0 billion, compared to the consensus revenue estimate of $12.6 billion.

What is Adam Schechter's approval rating as Laboratory Co. of America's CEO?

143 employees have rated Laboratory Co. of America Chief Executive Officer Adam Schechter on Glassdoor.com . Adam Schechter has an approval rating of 73% among the company's employees.

What other stocks do shareholders of Laboratory Co. of America own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Laboratory Co. of America investors own include Gilead Sciences (GILD) , Micron Technology (MU) , Intel (INTC) , Pfizer (PFE) , Johnson & Johnson (JNJ) , NVIDIA (NVDA) , Abbott Laboratories (abt) , AbbVie (ABBV) , Alibaba Group (BABA) and Amgen (AMGN) .

Who are Laboratory Co. of America's major shareholders?

Laboratory Co. of America's stock is owned by many different retail and institutional investors. Top institutional investors include American National Bank (0.05%), Cardinal Capital Management (0.04%), Global Assets Advisory LLC (0.03%), Cohen Klingenstein LLC (0.03%), Jacobs & Co. CA (0.03%) and Fragasso Group Inc. (0.02%). Insiders that own company stock include Amy B Summy , Brian J Caveney , Der Vaart Sandra D Van , Dwight Gary Gilliland , Glenn A Eisenberg , Jean-Luc Belingard , Jonathan P Divincenzo, Kerrii B Anderson , Mark S Schroeder , Paul R Kirchgraber , Peter J Wilkinson , Peter M Neupert and R Sanders Williams . View institutional ownership trends .

How do I buy shares of Laboratory Co. of America?

Shares of LH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

Does Laboratory Co. of America have any subsidiaries?

The following companies are subsidiares of Laboratory Co. of America: 1957285 Ontario Inc. dba Quality Underwriting Services, 2089729 Ontario Inc., 2248848 Ontario Inc., 3065619 Nova Scotia Company, 3257959 Nova Scotia Company, 8165335 Canada Inc., 8348596 Canada Inc., 896988 Ontario Limited, 9279-3280 Quebec Inc., Accupath Diagnostic Laboratories Inc., Assets of Pathology Inc, Beacon LBS IPA Inc., Beacon Laboratory Benefit Solutions Inc., CannAmm GP Inc., CannAmm Limited Partnership, Center for Disease Detection International, Center for Disease Detection LLC, Centrex Clinical Laboratories Inc., Chiltern, Clearstone Central Laboratories (U.S.) Inc., Clearstone Holdings (International) Ltd., Clinical Outreach Laboratory Services, Clipper Holdings Inc., Colorado Coagulation Consultants Inc., Colorado Laboratory Services LLC, Correlagen Diagnostics Inc., Covance Inc., Curalab Inc., Cytometry Associates Inc., Czura Thornton (Hong Kong) Limited, DCL Acquisition Inc., DCL Medical Laboratories LLC, DCL Sub LLC, DIANON Systems Inc., DL Holdings Limited Partnership, Decision Diagnostics L.L.C. (aka DaVinici/Medicorp LLC), Diagnostic Services Inc., DynaLifeDX, Dynacare - Gamma Laboratory Partnership, Dynacare Company, Dynacare G.P. Inc., Dynacare Holdco LLC, Dynacare Laboratories Inc., Dynacare Laboratories Limited Partnership, Dynacare Northwest Inc., Dynacare Realty Inc., DynalifeDX Infrastructure Inc., Envigo's nonclinical contract research services business, Esoterix Genetic Counseling LLC, Esoterix Genetic Laboratories LLC, Esoterix Inc., Execmed Health Services Inc., FirstSource Laboratory Solutions Inc., GDML Medical Laboratories Inc, Gamma Dynacare Central Medical Laboratories GP Inc., Gamma Dynacare Central Medical Laboratory Limited Partnership, HHLA Lab-In-An-Envelope LLC, Health Testing Centers Inc., Health Trans Services Inc., Home Healthcare Laboratory of America LLC, IDX Pathology Inc., Impact Genetics Corporation, Impact Genetics Inc., Kaleida LabCorp LLC, Lab Delivery Service of New York City Inc., LabCorp BVBA, LabCorp Belgium Holdings Inc., LabCorp Central Laboratories (Canada) Inc., LabCorp Central Laboratories (China) Inc., LabCorp Colorado Inc., LabCorp Development Company, LabCorp Employer Services Inc., LabCorp Health System Diagnostics LLC, LabCorp Indiana Inc., LabCorp Japan G.K., LabCorp Limited, LabCorp Michigan Inc., LabCorp Nebraska Inc., LabCorp Neon Ltd., LabCorp Neon Switzerland S.à.r.l., LabCorp Specialty Testing Billing Service Inc., LabCorp Specialty Testing Group Inc., LabCorp Staffing Solutions Inc., LabCorp Tennessee LLC, LabCorp UK Holdings Ltd., LabWest Inc., Laboratoire Bio-Medic Inc., Laboratory Corporation of America, Lifecodes Corporation, LipoScience Inc., Litholink Corporation, MEDTOX Scientific Inc., MNG Laboratories, MedAxio Insurance Medical Services GP Inc., MedAxio Insurance Medical Services LP, Medical Neurogenitics LLC, Medtox Diagnostics Inc., Medtox Laboratories Inc., Monogram Biosciences Inc., Monogram Biosciences UK Limited, Myriad Autoimmune’s Vectra Testing Business, NWT Inc., National Genetics Institute, New Brighton Business Center LLC, New Imaging Diagnostics LLC, New Molecular Diagnostics Ventures LLC, Orchid Cellmark ULC, Ovia Health, PA Labs Inc., Paclab LLC, Path Lab Incorporated, Pathology Associates Medical Lab LLC, Pee Dee Pathology Associates Inc., Personal Genome Diagnostics Inc., Persys Technology Inc., Pixel by LabCorp, Princeton Diagnostic Laboratories of America Inc., Protedyne Corporation, SW/DL LLC, Saint Josephs-PAML LLC, Sequenom Biosciences (India) Pvt. Ltd., Sequenom Inc, Sequenom Inc., Tandem Labs Inc., Toxikon Corporation, Tri-Cities Laboratory LLC, Viro-Med Laboratories Inc., Visiun, and Yakima Medical Arts Inc.. Read More

NYSE:LH

Laboratory Co. of America (LH) Stock Price, News & Analysis

→ Your eBook: Mastering Earnings Announcements Trading (From StockEarnings) (Ad)

Free LH Stock Alerts

$203.88

+0.56 (+0.28%)

(As of 02:58 PM ET)

Compare

Today's Range: $202.07
▼
$204.69
50-Day Range: $203.39
▼
$228.11
52-Week Range: $174.20
▼
$234.09

Volume: 360,895 shs
Average Volume: 732,161 shs
Market Capitalization: $17.15 billion

P/E Ratio: 43.66
Dividend Yield: 1.41%
Price Target: $243.50

Get Laboratory Co. of America alerts:

Laboratory Co. of America MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.79 Rating Score
Upside/Downside: 19.2% Upside
$243.50 Price Target
Short Interest: Healthy
2.29% of Float Sold Short
Dividend Strength: Moderate
Based on Four Factors
Sustainability: -0.66
Upright™ Environmental Score
News Sentiment: 0.46
Based on 18 Articles This Week
Insider Trading: Selling Shares
$11.76 M Sold Last Quarter
Proj. Earnings Growth: 7.88%
From $14.84 to $16.01 Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.66 out of 5 stars

Medical Sector

66th out of 930 stocks

Medical Laboratories Industry

2nd out of 20 stocks

2.4

Analyst's Opinion

Consensus Rating
Laboratory Co. of America has received a consensus rating of Moderate Buy. The company's average rating score is 2.79, and is based on 11 buy ratings, 3 hold ratings, and no sell ratings.
Amount of Analyst Coverage
Laboratory Co. of America has only been the subject of 4 research reports in the past 90 days.

4.0

Short Interest

Percentage of Shares Shorted
2.29% of the float of Laboratory Co. of America has been sold short.
Short Interest Ratio / Days to Cover
Laboratory Co. of America has a short interest ratio ("days to cover") of 2.6, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Laboratory Co. of America has recently decreased by 3.52%, indicating that investor sentiment is improving.

2.5

Dividend Strength

Dividend Yield
Laboratory Co. of America pays a meaningful dividend of 1.40%, higher than the bottom 25% of all stocks that pay dividends.
Dividend Growth
Laboratory Co. of America does not have a long track record of dividend growth.
Dividend Coverage
The dividend payout ratio of Laboratory Co. of America is 61.67%. This payout ratio is at a healthy, sustainable level, below 75%.
Dividend Sustainability
Based on earnings estimates, Laboratory Co. of America will have a dividend payout ratio of 17.99% next year. This indicates that Laboratory Co. of America will be able to sustain or increase its dividend.

4.2

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Laboratory Co. of America has received a 60.22% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Private genetic testing services", "Private clinical drug testing", "Private oncology diagnostics services", and "Private medical laboratory services" products. See details.
Environmental Sustainability
The Environmental Impact score for Laboratory Co. of America is -0.66.

1.9

News and Social Media Coverage

News Sentiment
Laboratory Co. of America has a news sentiment score of 0.46. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.66 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 18 news articles for Laboratory Co. of America this week, compared to 7 articles on an average week.
Search Interest
Only 6 people have searched for LH on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.
MarketBeat Follows
Only 4 people have added Laboratory Co. of America to their MarketBeat watchlist in the last 30 days. This is a decrease of -60% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Laboratory Co. of America insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $11,761,059.00 in company stock.
Percentage Held by Insiders
Only 0.85% of the stock of Laboratory Co. of America is held by insiders.
Percentage Held by Institutions
95.94% of the stock of Laboratory Co. of America is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

2.5

Earnings and Valuation

Earnings Growth
Earnings for Laboratory Co. of America are expected to grow by 7.88% in the coming year, from $14.84 to $16.01 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Laboratory Co. of America is 43.74, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 136.33.
Price to Earnings Ratio vs. Sector
The P/E ratio of Laboratory Co. of America is 43.74, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 192.09.
Price to Earnings Growth Ratio
Laboratory Co. of America has a PEG Ratio of 1.55. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
Laboratory Co. of America has a P/B Ratio of 2.20. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad StockEarnings

Your eBook: Mastering Earnings Announcements Trading

Trading around earnings announcements (Pre-Earnings, Into-Earnings, and Post-Earnings) provides a unique trading opportunity. That is because trading around earnings announcements presents short-term trading opportunities (these are great because they don’t tie your money up for very long).

Click Here to Claim Your FREE The Ultimate Strategy Guide To Trade Earnings E-Book .

About Laboratory Co. of America Stock (NYSE:LH)

Laboratory Corporation of America Holdings operates as a life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. It operates in two segments, Labcorp Diagnostics (Dx) and Biopharma Laboratory Services (BLS). The company offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, PAP tests, hemoglobin A1C and vitamin D, prostate-specific antigens, tests for sexually transmitted diseases, hepatitis C tests, microbiology cultures and procedures, and alcohol and other substance-abuse tests. It also provides specialty testing services comprising gene-based and esoteric testing; advanced tests target specific diseases; services related to anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, parentage and donor testing, occupational testing services, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests; and health and wellness services to employers and managed care organizations (MCOs), including health fairs, on-site and at-home testing, vaccinations, and health screenings. In addition, the company offers online and mobile applications that enable patients to check test results; online applications for providers, MCOs, and accountable care organizations; and drug development, medical device, and companion diagnostic development solutions from early-stage research to clinical development, as well as support for crop protection and chemical testing. It serves pharmaceutical, biotechnology, medical device, and diagnostics companies; and MCOs, employer plans, other health insurance providers, governmental agencies, physicians and other healthcare providers, hospitals and health systems, employers, patients and consumers, contract research organizations, crop protection and chemical companies, academic institutions, independent clinical laboratories, and retailers. The company was incorporated in 1994 and is headquartered in Burlington, North Carolina.

LH Stock Price History

30 days | 90 days | 365 days | Advanced Chart

LH Stock News Headlines

April 15, 2024 | marketbeat.com

How a 1% Dividend Equals 68% Yearly Gains

April 4, 2024 | insidertrades.com

Laboratory Co. of America Holdings (NYSE:LH) CMO Amy B. Summy Sells 3,500 Shares

April 16, 2024 | StockEarnings (Ad)

Your eBook: Mastering Earnings Announcements Trading

March 30, 2024 | insidertrades.com

Laboratory Co. of America Holdings (NYSE:LH) EVP Sells $770,077.22 in Stock

March 19, 2024 | marketbeat.com

LifeMD Shares Come Back to Life on GLP-1 Business Growth (LH)

LifeMD stock is surging as the company is riding the GLP-1 trend to double-digit revenue growth and projections for 67% earnings growth in 2024

April 15, 2024 | finance.yahoo.com

Laboratory Corporation of America Holdings (NYSE:LH) Has Announced A Dividend Of $0.72

April 15, 2024 | finance.yahoo.com

Labcorp Announces First-of-Its-Kind Test for Early Indication of Neurodegenerative Diseases and Brain Injuries Using a Blood Draw

April 14, 2024 | americanbankingnews.com

Laboratory Co. of America Holdings (NYSE:LH) Receives Average Rating of "Moderate Buy" from Analysts

April 16, 2024 | StockEarnings (Ad)

Your eBook: Mastering Earnings Announcements Trading

April 12, 2024 | msn.com

Labcorp wins FDA emergency use nod for monkeypox test

April 11, 2024 | msn.com

Laboratory Corporation of America declares $0.72 dividend

April 11, 2024 | prnewswire.com

Labcorp Declares Quarterly Dividend

April 10, 2024 | markets.businessinsider.com

Labcorp Says FDA Grants EUA For Mpox PCR Test Home Collection Kit

April 10, 2024 | prnewswire.com

Labcorp Receives FDA Emergency Use Authorization for Mpox PCR Test Home Collection Kit

April 8, 2024 | finance.yahoo.com

Do You Think Laboratory Corporation of America Holdings (LH) Valuation is Not Attractive Anymore?

April 8, 2024 | prnewswire.com

Labcorp Announces Expansion of Precision Oncology Portfolio to Support Pharmaceutical, Biopharma, and Clinical Research in Advancing Drug Development Programs

April 8, 2024 | americanbankingnews.com

Leerink Partnrs Weighs in on Laboratory Co. of America Holdings' Q1 2024 Earnings (NYSE:LH)

April 5, 2024 | prnewswire.com

Labcorp Launches Labcorp® Plasma Detect™ Extending Leadership into Molecular Residual Disease (MRD) Clinical Research

April 2, 2024 | finance.yahoo.com

Labcorp to Present Diverse Portfolio of Precision Oncology Research at the Annual Meeting of the American Association for Cancer Research

April 1, 2024 | finance.yahoo.com

Xcell Biosciences Strengthens Cell and Gene Therapy Collaboration With Labcorp

March 30, 2024 | finance.yahoo.com

Insider Sell: EVP, Chief Legal Officer van der Vaart Sandra D Sells 3,553 Shares of Laboratory ...

March 29, 2024 | bizjournals.com

Labcorp to pay $237.5M to acquire assets of BioReference Health's diagnostics business

March 29, 2024 | prnewswire.com

The Prelude Network® Names Labcorp Its Preferred Genetic Carrier Screening Lab

March 28, 2024 | markets.businessinsider.com

Labcorp To Acquire Select Assets Of BioReference Health - Quick Facts

March 28, 2024 | prnewswire.com

Labcorp Announces Acquisition of Select Assets of BioReference Health's Diagnostics Business

March 27, 2024 | finance.yahoo.com

Labcorp to Announce First Quarter Financial Results on April 25, 2024

March 25, 2024 | finance.yahoo.com

Laboratory Corporation of America Holdings: Upgrading to BUY with $250 target

See More Headlines

Receive LH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Laboratory Co. of America and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/15/2024
Ex-Dividend for 3/13 Dividend: 2/26/2024
Dividend Payable: 3/13/2024
Today: 4/16/2024
Next Earnings (Confirmed): 4/25/2024
Ex-Dividend for 6/12 Dividend: 5/24/2024
Dividend Payable: 6/12/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NYSE
Sector: Medical
Industry: Medical laboratories
Sub-Industry: Health Care Services
Current Symbol: NYSE:LH
Previous Symbol: NYSE:LH?
CUSIP: 50540R40
CIK: 920148
Web: www.labcorp.com
Phone: (336) 229-1127
Fax: 336-513-4510
Employees: 67,000
Year Founded: 1995

Price Target and Rating

Average Stock Price Target: $243.50
High Stock Price Target: $270.00
Low Stock Price Target: $210.00
Potential Upside/Downside: +19.2%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.79
Research Coverage: 14 Analysts

Profitability

EPS (Most Recent Fiscal Year): $4.67
Trailing P/E Ratio: 43.74
Forward P/E Ratio: 13.76
P/E Growth: 1.55
Net Income: $418 million
Net Margins: 3.24%
Pretax Margin: 4.68%
Return on Equity: 13.99%
Return on Assets: 6.82%

Debt

Debt-to-Equity Ratio: 0.52
Current Ratio: 1.17
Quick Ratio: 1.02

Sales & Book Value

Annual Sales: $12.16 billion
Price / Sales: 1.41
Cash Flow: $20.18 per share
Price / Cash Flow: 10.12
Book Value: $92.76 per share
Price / Book: 2.20

Miscellaneous

Outstanding Shares: 84,130,000
Free Float: 83,411,000
Market Cap: $17.18 billion
Optionable: Optionable
Beta: 1.01

Social Links

12 Stocks Corporate Insiders are Abandoning

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

Mr. Adam H. Schechter (Age 59)
President, CEO & Chairman
Comp: $3.72M
Mr. Glenn A. Eisenberg (Age 63)
CFO & Executive VP
Comp: $1.54M
Mr. Mark S. Schroeder (Age 63)
Executive VP, President of Diagnostics Laboratories & COO
Comp: $1.06M
Mr. Peter J. Wilkinson (Age 52)
Senior VP & Chief Accounting Officer
Mr. Lance V. Berberian (Age 61)
Executive VP and Chief Information & Technology Officer
Comp: $876.62k
Dr. Marcia T. Eisenberg Ph.D. (Age 64)
Chief Scientific Officer & Senior VP
Christin O'Donnell
Vice President of Investor Relations
Ms. Sandra D. van der Vaart (Age 64)
Executive VP, Chief Legal Officer, Chief Compliance Officer & Corporate Secretary
Ms. Amy B. Summy (Age 57)
Executive VP & Chief Marketing Officer
Ms. Anita Z. Graham (Age 53)
Executive VP & Chief Human Resources Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

Should I Buy Laboratory Co. of America Stock? LH Pros and Cons Explained

Pros

Here are some ways that investors could benefit from investing in Laboratory Co. of America Holdings:

Strong Stock Performance: Laboratory Co. of America Holdings has shown a consistent uptrend in its stock price, with a 12-month high of $234.09, indicating positive investor sentiment.
Positive Earnings Growth: The company reported $3.30 EPS for the last quarter, surpassing analyst estimates, showcasing strong financial performance.
Analyst Ratings: Laboratory Co. of America has received favorable ratings from analysts, with a consensus rating of "Moderate Buy" and a target price of $243.50, indicating growth potential.
Institutional Investor Interest: Notable institutional investors like SG Americas Securities LLC and Pallas Capital Advisors LLC have increased their stakes in the company, reflecting confidence in its future prospects.
Diverse Revenue Streams: With a revenue of $3.03 billion in the last quarter, Laboratory Co. of America has demonstrated resilience and stability in its revenue generation.

Cons

Investors should be bearish about investing in Laboratory Co. of America Holdings for these reasons:

Market Volatility: The stock has a beta of 1.02, indicating sensitivity to market fluctuations, which may pose risks to investors during turbulent market conditions.
Decreasing Revenue: The company experienced a 17.5% decline in quarterly revenue on a year-over-year basis, signaling potential challenges in revenue growth.
High Price-to-Earnings Ratio: With a P/E ratio of 46.78, the stock may be considered overvalued compared to industry peers, potentially limiting upside potential.
Debt Levels: Laboratory Co. of America has a debt-to-equity ratio of 0.52, which could raise concerns about the company's financial leverage and ability to manage debt obligations.
Competitive Landscape: The medical research industry is highly competitive, and Laboratory Co. of America may face challenges in maintaining market share and profitability amidst competition.

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Saturday, April 13, 2024. Please send any questions or comments about these Laboratory Co. of America pros and cons to contact@marketbeat.com.

LH Stock Analysis - Frequently Asked Questions

Should I buy or sell Laboratory Co. of America stock right now?: 14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Laboratory Co. of America in the last year. There are currently 3 hold ratings and 11 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" LH shares.
View LH analyst ratings or view top-rated stocks.
What is Laboratory Co. of America's stock price target for 2024?: 14 analysts have issued 12-month target prices for Laboratory Co. of America's stock. Their LH share price targets range from $210.00 to $270.00. On average, they anticipate the company's share price to reach $243.50 in the next twelve months. This suggests a possible upside of 19.2% from the stock's current price.
View analysts price targets for LH or view top-rated stocks among Wall Street analysts.
How have LH shares performed in 2024?: Laboratory Co. of America's stock was trading at $227.29 on January 1st, 2024. Since then, LH stock has decreased by 10.1% and is now trading at $204.26.
View the best growth stocks for 2024 here.
When is Laboratory Co. of America's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, April 25th 2024.
View our LH earnings forecast.
How can I listen to Laboratory Co. of America's earnings call?: Laboratory Co. of America will be holding an earnings conference call on Thursday, April 25th at 9:00 AM Eastern. Interested parties can register for or listen to the call using this link.
How were Laboratory Co. of America's earnings last quarter?: Laboratory Co. of America Holdings (NYSE:LH) posted its quarterly earnings data on Thursday, February, 15th. The medical research company reported $3.30 earnings per share for the quarter, beating the consensus estimate of $3.29 by $0.01. The medical research company had revenue of $3.03 billion for the quarter, compared to the consensus estimate of $3.02 billion. Laboratory Co. of America had a trailing twelve-month return on equity of 13.99% and a net margin of 3.24%. The firm's quarterly revenue was down 17.5% on a year-over-year basis. During the same period last year, the company earned $4.14 earnings per share.
Read the conference call transcript.
How often does Laboratory Co. of America pay dividends? What is the dividend yield for Laboratory Co. of America?: Laboratory Co. of America declared a quarterly dividend on Thursday, April 11th. Investors of record on Tuesday, May 28th will be paid a dividend of $0.72 per share on Wednesday, June 12th. This represents a $2.88 dividend on an annualized basis and a yield of 1.41%. The ex-dividend date is Friday, May 24th.
Read our dividend analysis for LH.
Is Laboratory Co. of America a good dividend stock?: Laboratory Co. of America (NYSE:LH) pays an annual dividend of $2.88 per share and currently has a dividend yield of 1.40%. The dividend payout ratio is 61.67%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, LH will have a dividend payout ratio of 17.99% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for LH.

What ETFs hold Laboratory Co. of America's stock?: ETFs with the largest weight of Laboratory Co. of America (NYSE:LH) stock in their portfolio include Amplify Treatments, Testing and Advancements ETF (GERM), Cambiar Aggressive Value ETF (CAMX), Vesper U.S. Large Cap Short-Term Reversal Strategy ETF (UTRN), Global X Telemedicine & Digital Health ETF (EDOC), iShares U.S. Healthcare Providers ETF (IHF), LeaderShares AlphaFactor Tactical Focused ETF (LSAT), BlackRock Large Cap Value ETF (BLCV) and Thrivent Small-Mid Cap ESG ETF (TSME).
What guidance has Laboratory Co. of America issued on next quarter's earnings?: Laboratory Co. of America updated its FY 2024 earnings guidance on Friday, February, 16th. The company provided earnings per share (EPS) guidance of 14.300-15.400 for the period, compared to the consensus earnings per share estimate of 14.600. The company issued revenue guidance of $12.7 billion-$13.0 billion, compared to the consensus revenue estimate of $12.6 billion.
What is Adam Schechter's approval rating as Laboratory Co. of America's CEO?: 143 employees have rated Laboratory Co. of America Chief Executive Officer Adam Schechter on Glassdoor.com. Adam Schechter has an approval rating of 73% among the company's employees.
What other stocks do shareholders of Laboratory Co. of America own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Laboratory Co. of America investors own include Gilead Sciences (GILD), Micron Technology (MU), Intel (INTC), Pfizer (PFE), Johnson & Johnson (JNJ), NVIDIA (NVDA), Abbott Laboratories (abt), AbbVie (ABBV), Alibaba Group (BABA) and Amgen (AMGN).
Who are Laboratory Co. of America's major shareholders?: Laboratory Co. of America's stock is owned by many different retail and institutional investors. Top institutional investors include American National Bank (0.05%), Cardinal Capital Management (0.04%), Global Assets Advisory LLC (0.03%), Cohen Klingenstein LLC (0.03%), Jacobs & Co. CA (0.03%) and Fragasso Group Inc. (0.02%). Insiders that own company stock include Amy B Summy, Brian J Caveney, Der Vaart Sandra D Van, Dwight Gary Gilliland, Glenn A Eisenberg, Jean-Luc Belingard, Jonathan P Divincenzo, Kerrii B Anderson, Mark S Schroeder, Paul R Kirchgraber, Peter J Wilkinson, Peter M Neupert and R Sanders Williams.
View institutional ownership trends.
How do I buy shares of Laboratory Co. of America?: Shares of LH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.
Does Laboratory Co. of America have any subsidiaries?: The following companies are subsidiares of Laboratory Co. of America: 1957285 Ontario Inc. dba Quality Underwriting Services, 2089729 Ontario Inc., 2248848 Ontario Inc., 3065619 Nova Scotia Company, 3257959 Nova Scotia Company, 8165335 Canada Inc., 8348596 Canada Inc., 896988 Ontario Limited, 9279-3280 Quebec Inc., Accupath Diagnostic Laboratories Inc., Assets of Pathology Inc, Beacon LBS IPA Inc., Beacon Laboratory Benefit Solutions Inc., CannAmm GP Inc., CannAmm Limited Partnership, Center for Disease Detection International, Center for Disease Detection LLC, Centrex Clinical Laboratories Inc., Chiltern, Clearstone Central Laboratories (U.S.) Inc., Clearstone Holdings (International) Ltd., Clinical Outreach Laboratory Services, Clipper Holdings Inc., Colorado Coagulation Consultants Inc., Colorado Laboratory Services LLC, Correlagen Diagnostics Inc., Covance Inc., Curalab Inc., Cytometry Associates Inc., Czura Thornton (Hong Kong) Limited, DCL Acquisition Inc., DCL Medical Laboratories LLC, DCL Sub LLC, DIANON Systems Inc., DL Holdings Limited Partnership, Decision Diagnostics L.L.C. (aka DaVinici/Medicorp LLC), Diagnostic Services Inc., DynaLifeDX, Dynacare - Gamma Laboratory Partnership, Dynacare Company, Dynacare G.P. Inc., Dynacare Holdco LLC, Dynacare Laboratories Inc., Dynacare Laboratories Limited Partnership, Dynacare Northwest Inc., Dynacare Realty Inc., DynalifeDX Infrastructure Inc., Envigo's nonclinical contract research services business, Esoterix Genetic Counseling LLC, Esoterix Genetic Laboratories LLC, Esoterix Inc., Execmed Health Services Inc., FirstSource Laboratory Solutions Inc., GDML Medical Laboratories Inc, Gamma Dynacare Central Medical Laboratories GP Inc., Gamma Dynacare Central Medical Laboratory Limited Partnership, HHLA Lab-In-An-Envelope LLC, Health Testing Centers Inc., Health Trans Services Inc., Home Healthcare Laboratory of America LLC, IDX Pathology Inc., Impact Genetics Corporation, Impact Genetics Inc., Kaleida LabCorp LLC, Lab Delivery Service of New York City Inc., LabCorp BVBA, LabCorp Belgium Holdings Inc., LabCorp Central Laboratories (Canada) Inc., LabCorp Central Laboratories (China) Inc., LabCorp Colorado Inc., LabCorp Development Company, LabCorp Employer Services Inc., LabCorp Health System Diagnostics LLC, LabCorp Indiana Inc., LabCorp Japan G.K., LabCorp Limited, LabCorp Michigan Inc., LabCorp Nebraska Inc., LabCorp Neon Ltd., LabCorp Neon Switzerland S.à.r.l., LabCorp Specialty Testing Billing Service Inc., LabCorp Specialty Testing Group Inc., LabCorp Staffing Solutions Inc., LabCorp Tennessee LLC, LabCorp UK Holdings Ltd., LabWest Inc., Laboratoire Bio-Medic Inc., Laboratory Corporation of America, Lifecodes Corporation, LipoScience Inc., Litholink Corporation, MEDTOX Scientific Inc., MNG Laboratories, MedAxio Insurance Medical Services GP Inc., MedAxio Insurance Medical Services LP, Medical Neurogenitics LLC, Medtox Diagnostics Inc., Medtox Laboratories Inc., Monogram Biosciences Inc., Monogram Biosciences UK Limited, Myriad Autoimmune’s Vectra Testing Business, NWT Inc., National Genetics Institute, New Brighton Business Center LLC, New Imaging Diagnostics LLC, New Molecular Diagnostics Ventures LLC, Orchid Cellmark ULC, Ovia Health, PA Labs Inc., Paclab LLC, Path Lab Incorporated, Pathology Associates Medical Lab LLC, Pee Dee Pathology Associates Inc., Personal Genome Diagnostics Inc., Persys Technology Inc., Pixel by LabCorp, Princeton Diagnostic Laboratories of America Inc., Protedyne Corporation, SW/DL LLC, Saint Josephs-PAML LLC, Sequenom Biosciences (India) Pvt. Ltd., Sequenom Inc, Sequenom Inc., Tandem Labs Inc., Toxikon Corporation, Tri-Cities Laboratory LLC, Viro-Med Laboratories Inc., Visiun, and Yakima Medical Arts Inc..
Read More

This page (NYSE:LH) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Laboratory Co. of America (LH) Stock Price, News & Analysis

Laboratory Co. of America MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Laboratory Co. of America Stock (NYSE:LH)

LH Stock Price History

LH Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Social Links

Key Executives

Key Competitors

Insiders & Institutions

Should I Buy Laboratory Co. of America Stock? LH Pros and Cons Explained

Pros

Cons

LH Stock Analysis - Frequently Asked Questions

Overall MarketRank^™